Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6092588 | 1.00 | HCAR2 (0.53) | HCAR2ALDH1A1SMN1; SMN2HSD11B1ABCG2 | |
| SCHEMBL17448532 | 0.79 | HCAR2 (0.46) | HCAR2ALDH1A1SMN1; SMN2ABCG2LMNA | |
| SCHEMBL5246063 | 0.76 | HCAR2 (0.69) | HCAR2ALDH1A1SMN1; SMN2ABCG2LMNA | |
| SCHEMBL3382206 | 0.76 | HCAR2 (0.69) | HCAR2ALDH1A1SMN1; SMN2ABCG2LMNA | |
| SCHEMBL16052932 | 0.75 | MEN1 (0.38) | ALDH1A1SMN1; SMN2HSD11B1LMNAMAPT | |
| SCHEMBL16052931 | 0.75 | MEN1 (0.38) | ALDH1A1SMN1; SMN2HSD11B1LMNAMAPT | |
| SCHEMBL6091145 | 0.75 | GABBR2 (0.53) | HCAR2ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL12040547 | 0.75 | GABBR2 (0.53) | HCAR2ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL3431569 | 0.73 | HSD11B1 (0.45) | ALDH1A1SMN1; SMN2HSD11B1LMNAMAPT | |
| SCHEMBL8068014 | 0.73 | JUN (0.51) | ALDH1A1SMN1; SMN2HSD11B1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160016860-A1 | METHODS FOR PHOSPHINE OXIDE REDUCTION IN CATALYTIC WITTIG REACTIONS | DUBLIN CITY UNIVERSITY (IE) | 2016-01-21 | — | — | US | disclosed |
| US-20160016860-A1 | METHODS FOR PHOSPHINE OXIDE REDUCTION IN CATALYTIC WITTIG REACTIONS | DUBLIN CITY UNIVERSITY (IE) | 2016-01-21 | — | — | US | disclosed |
| WO-2014140353-A1 | METHODS FOR PHOSPHINE OXIDE REDUCTION IN CATALYTIC WITTIG REACTIONS | DUBLIN CITY UNIVERSITY (IE) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016860-A1 | METHODS FOR PHOSPHINE OXIDE REDUCTION IN CATALYTIC WITTIG REACTIONS | DCXR, TECR, PWWP2B | HCAR2 3518/4885ALDH1A1 4341/4885SMN1; SMN2 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.